The present invention relates to an anti-LILRB1 antibody having increased specificity for LILRB1, and to uses thereof. Specifically, an anti-LILRB1 antibody or an antigen-binding fragment thereof, and uses thereof in treating cancer are provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
2.
NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF
The present invention relates to a biaryl derivative compound, which exhibits the activity of a diacylglycerol acyltransferase 2 (DGAT2) inhibitor and is represented by chemical formula (1), a pharmaceutical composition comprising same as an active ingredient, and a use thereof.
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
3.
USE OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST FOR TREATMENTOF ATOPIC DERMATITIS
The present invention relates to use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the prevention or treatment of atopic dermatitis.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
The present invention relates to an amorphous compound represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The amorphous compound represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
5.
CRYSTALLINE FORM IV OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
The present invention relates to a crystalline form IV represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form IV represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
6.
CRYSTALLINE FORM II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
The present invention relates to a crystalline form II represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form II represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to a stable oral formulation comprising 1-(3-cyano-1-isopropyl-indol-5-yl) pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof as an API. The stable oral formulation according to the present invention has the characteristics of maintaining stability even if it does not comprise a stabilizer as an excipient, and does not comprise a stabilizer but has increased API content, and thus the convenience of administration can be increased.
The present invention provides a crosslinked hyaluronic acid hydrogel in which a crosslinking agent and a polyol are used to reduce toxicity during crosslinking, and thereby enhance safety while increasing persistence in the body; and a filler composition including the crosslinked hyaluronic acid hydrogel.
The present invention relates to a polypeptide binding to mucin 1, an isolated polynucleotide encoding same, a vector carrying the polynucleotide, and a cell including the vector. In addition, the present invention relates to a chimeric antigen receptor including the polypeptide binding to mucin 1, an isolated polynucleotide encoding the chimeric antigen receptor, a vector carrying the polynucleotide, an immune cell expressing the chimeric antigen receptor, a composition comprising same for treatment of cancer, and a method for treatment of cancer.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present disclosure relates to a composite filler comprising: porous inorganic particles including a sintered body of calcium-based particles and pores distributed in the sintered body; and a biodegradable carrier, and a product including the same.
A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
The present disclosure pertains to a GUCY2C-binding polypeptide and uses thereof and, specifically, to a GUCY2C-binding polypeptide, a fusion protein including same, a chimeric antigen receptor, an immune cell expressing the chimeric antigen receptor, and a use thereof for treatment and/or diagnosis of cancer.
The present disclosure relates to a polylactide resin composition prepared by combining specific nucleating agents and heat-treating them, which is characterized by having an excellent crystallinity degree.
The present invention relates to a method for preparing an intermediate for synthesis of a xanthine oxidase inhibitor and, more specifically, to a method for preparing compounds of chemical formulas 2 and 4 by using low-priced starting materials and ligands and employing chelating extraction and purification techniques.
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to an oral formulation that contains an API selected from 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and does not contain pH adjusting agents as excipients. The oral formulation according to the present invention does not contain pH adjusting agents, and thus has the advantages of having increased productivity and convenience of dosage, as well as a high dissolution rate, despite having a high API content.
The present invention relates to a method for preparing a xanthine oxidase inhibitor and, more specifically, to a method for preparing a compound of chemical formula 2 by using ester hydrolysis and a recrystallization method.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
16.
POLYLACTIDE RESIN COMPOSITION EXCELLENT IN CRYSTALLINITY DEGREE, AND METHOD FOR PREPARING THE SAME
The present disclosure relates to a polylactide resin composition that is used in combination with a specific nucleating agent, which is excellent in crystallinity degree and excellent in dispersibility between components and thus, also is excellent in transparency. Accordingly, it is possible to maintain the properties inherent in the polylactide resin according to the present disclosure while having excellent processability.
Disclosed is a coating thickness measuring apparatus and method. The coating thickness measuring apparatus according to an embodiment of the present disclosure includes a data obtaining unit configured to obtain thickness data indicating a thickness of a coating material applied to a contact portion of a substrate in contact with a coating roll while the substrate coated with the coating material is transported by the coating roll; and a processor configured to create a virtual memory zone having a plurality of storage areas in which correction data is distributed and stored and correct the thickness data based on the correction data pre-stored in a target storage area selected from the plurality of storage areas to generate corrected thickness data.
G01B 5/00 - Measuring arrangements characterised by the use of mechanical techniques
G01B 11/06 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness for measuring thickness
G01B 21/04 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring length, width, or thickness by measuring coordinates of points
G01B 21/08 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring length, width, or thickness for measuring thickness
The present disclosure has a feature that by using a specific branching agent and a phosphorus-based compound and an anhydride-based compound in the polylactide resin, a high degree of branching of the polylactide resin, which has not been achieved hitherto, can be achieved, and it can also be applied to processes that were difficult to apply to conventional polylactide resins such as expanded foam.
The present disclosure relates to a polylactide resin composition used in combination with a specific nucleating agent, which can relatively increase only the mobility of high molecular weight of the polylactide resin to improve the crystallinity degree, and at the same time, makes an amorphous region of the polylactide resin have a low glass transition temperature, thereby lowering the glass transition temperature of the polylactide resin composition, and simultaneously improving the crystallinity degree thereof.
The present disclosure has a feature that a specific branching agent, a phosphorus-based compound and an organic acid anhydride are used in the polylactide resin, thereby enabling highly branching of the polylactide resin, which has not been achieved hitherto, and improving several physical properties, especially melt strength, compared to conventional polylactide resins, and it can be applied even to processes that were difficult to apply to conventional polylactide resins such expanded foam.
A coating thickness measuring device according to an aspect of the present invention pertains to a coating thickness measuring device configured to measure the thickness of a coating material applied to a substrate supplied in a state of being wound on a coating roll, and the coating thickness measuring device comprises a coating thickness measuring module comprising: a light application part for applying light to the surface of coating material applied to a wound portion of the substrate around the coating roll, a light acquisition part for acquiring light reflected from the surface of the coating material, and a processor for calculating the thickness of the coating material on the basis of the acquired light.
G01B 11/06 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness for measuring thickness
G01B 21/04 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring length, width, or thickness by measuring coordinates of points
Provided is a method for preparing isopropyl alcohol including: (S1) passing reaction water through a first heat exchanger and a second heat exchanger to heat the reaction water, (S2) supplying the reaction water passed through the second heat exchanger to a reactor as a feed stream with a propylene monomer to produce a gaseous reaction product including isopropyl alcohol (IPA), (S3) purifying the isopropyl alcohol from the gaseous reaction product and recovering process water, and (S4) passing the process water through the second heat exchanger to cool the process water, and transferring a portion of the cooled process water to the first heat exchanger, wherein the reaction water is brought into contact with the portion of the cooled process water in the first heat exchanger for primary heating, and then brought into contact with the process water in the second heat exchanger for secondary heating.
C07C 29/04 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by addition of hydroxy groups to unsaturated carbon-to-carbon bonds, e.g. with the aid of H2O2 by hydration of carbon-to-carbon double bonds
C07C 29/76 - SeparationPurificationStabilisationUse of additives by physical treatment
C07C 29/88 - SeparationPurificationStabilisationUse of additives by treatment giving rise to a chemical modification of at least one compound
C07C 31/10 - Monohydroxylic acyclic alcohols containing three carbon atoms
C07C 31/12 - Monohydroxylic acyclic alcohols containing four carbon atoms
23.
POSITIVE ELECTRODE ACTIVE MATERIAL, PREPARATION METHOD THEREOF, AND LITHIUM SECONDARY BATTERY INCLUDING THE POSITIVE ELECTRODE ACTIVE MATERIAL
The present invention relates to a cathode active material and, more specifically, to a cathode active material, a preparation method therefor, and a lithium secondary battery comprising same, the cathode active material comprising a lithium composite transition metal oxide in a single particle form, and a cobalt-containing coating part formed on the lithium composite transition metal oxide in a single particle form, wherein the cobalt-containing coating part has, in the direction from the surface of the cathode active material to the center thereof, a phase gradient from a spinel structure to a layered structure.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
The present invention provides a method for preparing isopropyl alcohol, and an apparatus for carrying out the method, the method comprising the steps of: (S1) supplying a feed stream, containing a propylene monomer and water, to a reactor in the presence of a catalyst to perform a gas phase reaction; (S2) partially condensing a reaction product, obtained by means of the gas phase reaction, in a heat exchanger, and then transferring the uncondensed gas phase reaction product to an absorption tower and a portion of the condensed liquid phase reaction product to a pH measurement system connected on-line between the heat exchanger and the absorption tower; (S3) calculating the catalyst content by measuring the pH of the liquid reaction product transferred to the pH measuring system, and supplementing the reactor with the catalyst in an amount corresponding to the calculated content; and (S4) separating isopropyl alcohol contained in the gas phase reaction product in the absorption tower by dissolving the isopropyl alcohol in absorbing water.
C07C 29/03 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by addition of hydroxy groups to unsaturated carbon-to-carbon bonds, e.g. with the aid of H2O2
C07C 29/88 - SeparationPurificationStabilisationUse of additives by treatment giving rise to a chemical modification of at least one compound
C07C 31/10 - Monohydroxylic acyclic alcohols containing three carbon atoms
25.
METHOD FOR PREPARING POSITIVE ELECTRODE ACTIVE MATERIAL
The present invention pertains to a method for producing a positive electrode active material capable of providing a battery having excellent initial capacity and life characteristics, the method comprising the steps of: (A) preparing a first sintered product by mixing a positive electrode active material precursor, which contains at least 80 mol% of nickel (Ni) on the basis of the total metal content, and a lithium-containing raw material, and then performing a first sintering; and (B) preparing a lithium transition metal oxide by mixing the first sintered product and a nickel compound and then performing a second sintering, wherein the nickel compound is added such that the mol% of nickel contained in the nickel compound is greater than 0.01 mol% and less than 0.15 mol% on the basis of the total number of moles of metals contained in the positive electrode active material precursor.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
26.
POSITIVE ELECTRODE ACTIVE MATERIAL AND METHOD FOR PRODUCING THE SAME
The present invention relates to a method for producing a positive electrode active material which can minimize the surface degradation of a positive electrode active material which occurs i n a washi ng process, effectively control residual lithium, and form a uniform coating layer on the surface of the positive electrode active material, and a positive electrode active material produced by the method, the method including the steps of: (A) preparing a lithium transition metal oxide; ( B) mixing the lithium transition metal oxide and a first washing solution to first wash and then first filter the lithium transition metal oxide; (C) simultaneously second washing and second filtering the lithium transition metal oxide through step ( B) using a filter device capable of washing and filtering simultaneously with a second washing solution; and ( D) drying the lithium transition metal oxide through step ( C) , then mixing a coating element-containing raw material with the dried lithium transition metal oxide and heat-treating the mixture to form a coating layer, wherein the coating element containing raw material includes a boron- containing raw material and at least one lithium - containing raw material selected from among Li OH, Li2CO3, and Li2O.
C01B 35/10 - Compounds containing boron and oxygen
C01G 53/42 - Complex oxides containing nickel and at least one other metal element containing alkali metals, e.g. LiNiO2
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
The present invention relates to a positive electrode active material for a lithium secondary battery and a method for preparing the positive electrode active material.
C01G 53/44 - Complex oxides containing nickel and at least one other metal element containing alkali metals, e.g. LiNiO2 containing manganese
C01G 53/502 - Complex oxides containing nickel and at least one other metal element containing alkali metals, e.g. LiNiO2 containing manganese of the type (MnO2)n-, e.g. Li(NixMn1-x)O2 or Li(MyNixMn1-x-y)O2 containing lithium and cobalt
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/1315 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx containing halogen atoms, e.g. LiCoOxFy
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
A positive electrode active material in a form of a single particle includes a lithium transition metal oxide in a form of a single particle, a coating portion containing cobalt which is formed on the lithium transition metal oxide in the form of a single particle, and LiCo02 in a form of an island which is discontinuously formed on a surface. A ratio of an intensity of a peak ranging from 550 cm-1 to 620 cm-1 corresponding to an Alg vibration mode of LiCo02 to an intensity of a peak ranging from 500 cm-1 to 600 cm-1 corresponding to an Alg vibration mode of LiNi02 in a Raman spectrum of the surface is in a range of 0.1 to 1. Also provided is a method of preparing a positive electrode active material in a form of a single particle.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
29.
CATALYST FOR REFORMING METHANE, METHOD FOR PRODUCING SAME, AND METHOD FOR REFORMING METHANE
The present application has been made in an effort to provide a catalyst for methane reformation, a method for manufacturing the same, and a methane reforming method.
C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
30.
CATALYST FOR REFORMING METHANE AND METHOD FOR PRODUCING SAME
The present application provides a catalyst for methane reformation and a method for manufacturing the same. The catalyst for methane reformation includes a porous metal support; a primary coating layer provided on the porous metal support; and a secondary coating layer provided on the primary coating layer, wherein the primary coating layer includes a perovskite-based compound with a coefficient of thermal expansion of 65% or greater compared to a coefficient of thermal expansion of the porous metal support, wherein the secondary coating layer includes a perovskite-based catalyst particle and a perovskite-based binder, and wherein the perovskite-based catalyst particle and the perovskite-based binder each independently include a compound represented by Chemical Formula 1 above.
B01J 37/02 - Impregnation, coating or precipitation
C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
31.
DEVICE FOR MEASURING TEMPERATURE AND THICKNESS OF FILM AND MEASUREMENT METHOD USING SAME
The present disclosure relates to a film temperature and thickness measurement apparatus and a measurement method using the same, which can enable manufacturing of a film with a uniform thickness by sequentially measuring the surface temperature and thickness of a film at the same point of the film that is extruded or coating molded in an in-line method, and through control of the temperature and the thickness of the film based on the measured data.
A cylindrical battery cell, according to one embodiment of the present invention, comprises: an electrode assembly including a first electrode tab having a first polarity and a second electrode tab having a second polarity; a battery can that has an open portion formed at a lower end and a closed portion formed at an upper end, accommodates the electrode assembly through the open portion, and is electrically connected to the second electrode tab; a cell terminal that is electrically connected to the first electrode tab, exposed to the outside of the battery can through the closed portion of the battery can, and electrically insulated from the battery can; a first current collector plate having a first surface and a second surface opposite to the first surface, wherein the first surface is coupled to the first electrode tab and the second surface is coupled to the cell terminal; and a terminal fastening member that mechanically fastens the cell terminal and the first current collector plate.
H01M 50/179 - Arrangements of electric connectors penetrating the casing adapted for the shape of the cells for cells having curved cross-section, e.g. round or elliptic
H01M 50/50 - Current conducting connections for cells or batteries
H01M 50/528 - Fixed electrical connections, i.e. not intended for disconnection
H01M 50/538 - Connection of several leads or tabs of wound or folded electrode stacks
H01M 50/559 - Terminals adapted for cells having curved cross-section, e.g. round, elliptic or button cells
H01M 50/562 - Terminals characterised by the material
33.
ELECTROLYTE FOR LITHIUM-SULFUR SECONDARY BATTERY AND LITHIUM-SULFUR SECONDARY BATTERY COMPRISING THE SAME
LG MANAGEMENT DEVELOPMENT INSTITUTE (Republic of Korea)
LG ENERGY SOLUTION, LTD. (Republic of Korea)
LG CHEM, LTD. (Republic of Korea)
Inventor
Park, Seonghyo
Jeon, Hyelim
Cha, Sunyoung
Lee, Boram
Lee, Changhoon
Yoo, Solji
Jang, Eunji
Han, Kyeong Hwan
Kwack, Hobeom
Han, Sehui
Park, Changyoung
Lee, Jaewan
Abstract
The present invention relates to an electrolyte for lithium-sulfur secondary batteries that can improve the output characteristics of the lithium-sulfur secondary batteries, and to a lithium-sulfur secondary battery containing same. The electrolyte for lithium-sulfur secondary batteries includes a lithium salt, a non-aqueous solvent, and an additive, and respective certain ranges for the first mixture energy (Gmix1) of the electrolyte with dilithio peroctasulfide (Li2S8) and the second mixture energy (Gmix2) of the electrolyte with lithium sulfide (Li2S).
The present invention relates to a positive electrode material, which includes a first lithium transition metal oxide and a second lithium transition metal oxide having a smaller average particle diameter (D50) than the first lithium transition metal oxide, wherein particle strength of the first lithium transition metal oxide is 100 MPa or more, and particle strength of the second lithium transition metal oxide is twice or more than the particle strength of the first lithium transition metal oxide, and a positive electrode and a lithium secondary battery which include the same.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
The present invention relates to a cathode active material and a manufacturing method therefor, the cathode active material comprising: a lithium transition metal oxide in a single grain form; and a coating part formed on the surface of the lithium transition metal oxide in a single grain form and containing cobalt, wherein: the lithium transition metal oxide ina single grainform includes a boundary surface divided into a strong boundary having layered stmeture collapses and a weak boundary having no layered structure collapses within a crystal grain; and the coating part is formed on only the strong boundary.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
36.
SEPARATOR AND ELECTROCHEMICAL CONVERSION CELL INCLUDING THE SAME
The present invention relates to a separator including a base membrane, and a hydrophilic porous structure layer or a hydrophobic porous structure layer, which is stacked on at least one side of the base membrane, wherein the base membrane is an anion exchange membrane, a cation exchange membrane, or an amphoteric ion exchange membrane.
The present invention relates to: a positive electrode active material in the form of a single particle, wherein the positive electrode active material includes a lithium composite transition metal oxide in the form of a single particle, and the lithium composite transition metal oxide includes Al, Y, and Zr; a method for preparing the positive electrode active material; and a positive electrode and a lithium secondary battery including the same.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
38.
COMBINATION THERAPY FOR PREVENTING OR TREATING OBESITY
The present invention relates to a combination therapy for effectively preventing or treating obesity. More specifically, the objective of the present invention is to effectively prevent or treat obesity through a synergistic effect obtained when a melanocortin-4 receptor (MC4R) agonist and a glucagon-like peptide-1 (GLP-1) receptor agonist are administered in combination.
The present invention relates to a positive electrode active material including: a lithium transition metal oxide which is in the form of a single particle and divided into a surface part and a core; a coating part which is formed on the surface part and contains cobalt; and an island part which is discontinuously formed on at least one selected from the group consisting of the surface part and the coating part, wherein the island part contains 0.08-2.50 mol% of at least one selected from the group consisting of aluminum (Al) and zirconium (Zr), based on the total number of moles of the positive electrode active material, and a method for producing the positive electrode active material.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
40.
POSITIVE ELECTRODE ACTIVE MATERIAL AND METHOD FOR PRODUCING THE SAME
The present invention relates to a positive electrode active material including: a lithium transition metal oxide which is in the form of a single particle and divided into a surface part and a core; and a coating part which is formed on the surface part and contains cobalt, wherein the cobalt and nickel are contained in an amount satisfying a Co/Ni value (mol/mol) of 0.1 to 0.8 based on the entirety of the surface part and the coating part, and a method for producing the positive electrode active material.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
41.
METHOD OF PREPARING POSITIVE ELECTRODE ACTIVE MATERIAL AND THE POSITIVE ELECTRODE ACTIVE MATERIAL
The present invention relates to a method of preparing a positive electrode active material and the positive electrode active material, and to a method of preparing a positive electrode active material which includes steps of: (A) preparing a composite transition metal hydroxide containing zirconium by a co-precipitation reaction while adding a transition metal-containing solution containing at least one selected from nickel, cobalt, and manganese, a zirconium-containing raw material, an ammonium cationic complexing agent, and a basic solution into a reactor; and (B) preparing a lithium composite transition metal oxide by mixing the composite transition metal hydroxide containing zirconium with a lithium-containing raw material and an aluminum-containing raw material and sintering the mixture, wherein the lithium composite transition metal oxide includes zirconium, aluminum, and at least one selected from nickel, cobalt, and manganese, and the positive electrode active material prepared by the preparation method.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
The present invention relates to a biodegradable resin composition including heterogeneous biodegradable resins, which has improved compatibility between the heterogeneous biodegradable resins and thus the resin composition is excellent in 5 processibility by preventing an increase in viscosity while having excellent mechanical properties, and also relates to a biodegradable molded article molded from the biodegradable resin composition.
C08L 33/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen, and oxygen, the oxygen atom being present only as part of the carboxyl radical
C08L 33/12 - Homopolymers or copolymers of methyl methacrylate
C08L 67/02 - Polyesters derived from dicarboxylic acids and dihydroxy compounds
C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
43.
METHOD OF EVALUATING QUALITY OF POSITIVE ELECTRODE ACTIVE MATERIAL, POSITIVE ELECTRODE ACTIVE MATERIAL AND METHOD OF PREPARING POSITIVE ELECTRODE
The present invention relates to a method of evaluating quality of a positive electrode active material, which includes a step of (A) determining the positive electrode active material as a working product when a Raman shift value of a peak corresponding to an A1g vibration mode of LiNiO2 in a Raman spectrum of a surface of the positive electrode active material satisfies pre-established positive electrode active material quality evaluation criteria, a positive electrode active material which is determined as a working product by the method and may further improve performance of a battery, and a method of preparing a positive electrode which includes a step of evaluating quality of the positive electrode active material by the method of evaluating quality of a positive electrode active material.
G01N 21/88 - Investigating the presence of flaws, defects or contamination
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
44.
BRANCHED POLYLACTIC ACID POLYMER AND METHOD FOR PREPARING THE SAME
The present invention relates to a branched polylactic acid polymer which is branched and has improved rheological properties, and a method for preparing the same, and provides a branched polylactic acid polymer including a derived unit from a polylactic acid polymer, having an average number of long chain branches per molecule of 3 to 10, and having a mass flow rate measured under 190°C and 2.16 kg load based on ASTM D1238 conditions of 1 g/10 min to 20 g/10 min, and a method for preparing the same.
C08G 63/91 - Polymers modified by chemical after-treatment
C08L 33/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen, and oxygen, the oxygen atom being present only as part of the carboxyl radical
C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
The present invention relates to an isoxazoline derivative as an inhibitor against various caspases, a process for preparing the same, and a therapeutic composition for preventing inflammation and apoptosis comprising the same. The isoxazoline derivative corresponds to the compound of formula (I)
C07D 261/04 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
46.
POLYBENZIMIDAZOLE-BENZAMIDE COPOLYMER, PROCESS FOR PREPARING THE SAME, ELECTROLYTE MEMBRANE PREPARED THEREFROM AND PROCESS FOR PREPARING THE SAME
The present invention relates to a novel polybenzimidazole-benzamide copolymer composed of the repeating units represented by formula 1 which is applicable to the electrolyte membrane of fuel cell and a preparation method of the same. The present invention also relates to an electrolyte membrane produced from the above copolymer of the invention and a preparation method thereof. The present invention further relates to a membrane-electrode unit for fuel cell containing the electrolyte membrane of the invention and a fuel cell system including the unit. The electrolyte membrane prepared by the polybenzimidazole-benzamide copolymer of the invention has improved proton conductivity, compared with the conventional polybenzimidazole polymer membrane, and has thermal and chemical stability in addition to the operating capacity in a wide temperature range.
C08F 226/06 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
Starting from ethyl 3-(2,6-dichloro-5-fluoropyridin-3-yl)-3-oxo-propanoate (1), the present invention provides highly pure 7-chloro-1-cyclopropyl-6- fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (5) inone-potfour stepsusing a single solvent.
The present invention relates to a branched and sulphonated multi block copolymer and an electrolyte membrane using the same, more precisely, a branched and sulphonated multi block copolymer composed of the repeating unit represented by formula 1 and a preparation method thereof, a hydrogenated
branched and sulphonated multi block copolymer, a branched and sulphonated multi block copolymer electrolyte membrane and a fuel cell to which the branched and sulphonated multi block copolymer electrolyte membrane is applied.
The electrolyte membrane of the present invention has high proton conductivity and excellent mechanical properties as well as chemical stability, so it can be effectively used for the production of thin film without the decrease of membrane properties according to the increase of sulfonic acid group since it enables the regulation of the distribution, the location and the number of sulfonic acid group in polymer backbone.
C08G 65/40 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols from phenols and other compounds
Provided are a nanocomposite composition having barrier properties and an article manufactured therefrom. The compositon is prepared by dry-blending a polyolefin resin, a melt blend of a resin having barrier properties and a nanocomposite having barrier properties, and a compatibilizer. The compositon has superior barrier properties and moldability, and thus is useful for manufacturing a sheet or film having barrier properties.
Disclosed is an electrode catalyst comprising: (a) a support with a specific surface area of at least 1200 m /g; and (b) platinum or platinum-containing alloy particles on the support, wherein the platinum is supported on the electrode catalyst in an amount of 56~90 wt% based on the total weight of the electrode catalyst. A membrane electrode assembly (MEA) comprising the electrode catalyst and a fuel cell using the MEA are also disclosed. The electrode catalyst comprises platinum or platinum-containing alloy particles highly dispersed on a support with a large surface area in an amount of 56 wt% or more, and thus has an extended catalytically active region, resulting in improvement in the quality of a fuel cell.
The present invention relates to a cross-linked polyethylene composition having outstanding sweat-out inhibition and insulation properties. The composition of the invention characteristically comprises (A) 100 weight part of polyethylene; (B) 0.2 - 0.6 weight part of a mixture of a liquid antioxidant and a hindered phenol or thio ester antioxidant; (C) 0.2 - 0.9 weight part of polyethylene glycol having a molecular weight of 5,000 - 70,000; and (D) 1 - 4 weight part of a cross-linking agent.
H01B 3/42 - Insulators or insulating bodies characterised by the insulating materials; Selection of materials for their insulating or dielectric properties mainly consisting of organic substances waxes polyesters, polyethers, polyacetal
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
53.
DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE AGENT
Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.
The present invention relates to novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
55.
METHOD OF PREPARING 3-AMINO-4-(2-OXO-PIPERIDIN-1-YL)-BUTYRIC ACID DERIVATIVE FOR SYNTHESIZING MEDICAMENT
The present invention relates to a novel method for preparing a compound of formula (2) as the intermediate, which can be effectively used for preparation of a compound of formula (1) exhibiting good inhibitory activity against dipeptidyl peptidase IV enzyme.
A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 211/36 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
The present invention provides a pressure sensitive adhesive tape comprising: an acrylic foam layer; and rubber-based adhesive layers which are formed on both sides of said acrylic foam layer, wherein the content of gel in said rubber-based adhesive layers is 40% or more. Furthermore, in order to accomplish the object of the present invention, a method for manufacturing a pressure sensitive adhesive layer is provided, and the method comprises the steps of: manufacturing an acrylic foam layer; and forming rubber-based adhesive layers on one side or both sides of said acrylic foam layer, wherein said step of forming the rubber-based adhesive layers comprises the steps of: manufacturing a styrene block copolymer; forming rubber-based adhesive layers by adding an adhesive additive and a plasticizer to said styrene block copolymer; and setting the content of gel in said rubber-based adhesive layers to 40% or more.
C09J 121/00 - Adhesives based on unspecified rubbers
57.
PHARMACEUTICAL COMPOSITION FOR INHIBITING IMMUNE RESPONSE THROUGH INDUCING DIFFERENTIATION INTO REGULATOR T CELLS AND PROMOTING PROLIFERATION OF REGULATOR T CELLS
The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
The present invention relates to a plasticizer composition and a resin composition comprising the same. The plasticizer composition comprises: a terephthalate-based material comprising dibutyl terephthalate, butyl(2-ethylhexyl) terephthalate and di(2-ethylhexyl) terephthalate; and a glyceride-based material, and the plasticizer composition can improve mechanical properties such as tensile strength, elongation and modulus and can maintain the characteristics of a terephthalate-based material having excellent transmittance, transparency and migration loss characteristics.
The present invention relates to a plasticizer composition comprising: two or more terephthalates which are identical-carbon number types whereby the carbon numbers of alkyl groups bound to two ester groups are identical to each other; and one or more terephthalate which is a different-carbon number type whereby the carbon numbers of alkyl groups bound to two ester groups are different from each other, wherein the different-carbon number type comprises both a higher alkyl and a lower alkyl, the higher alkyl being selected from alkyl having a carbon number of at most 8, and the lower alkyl being selected from alkyl having a carbon number of at least 5. When applied to a resin, the plasticizer composition may improve effects such as viscosity stability, migration resistance and stress tolerance, and may enable plasticization efficiency and mechanical properties to be maintained at and improved by the same level or higher.
The present invention relates to a method for preparing an organic zinc catalyst through solid phase mixing that does not require a solvent and a washing process, and a method for preparing a polyalkylene carbonate resin using the organic zinc catalyst prepared thereby.
The present invention relates to a method for separating an organic zinc catalyst dispersed in a polyalkylene carbonate resin solution by filtering the polyalkylene carbonate resin solution. When using the method for separating an organic zinc catalyst according to the resent invention, organic zinc catalyst particles are efficiently removed from a polyalkylene carbonate resin solution, so that a transparent, high-purity polyalkylene carbonate solution can be obtained.
A hyaluronic acid filler according to the present invention not only exhibits an improved high lift capacity so as to maintain the shape of the skin for a long period of time while having a low probability for movement when injected into the skin, but also has a very low injection pressure during injection so as to reduce wrinkles and restore or expand the volume of soft tissues such as that of the cheeks, breasts, nose, lips, and buttocks, and is excellent when used for contour correction. Even when crosslinking agents are used sparingly in the manufacturing process, the hyaluronic acid filler has increased residence time in the human body and causes patients less pain.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to a polyalkylene carbonate-polylactic acid composite including non-halogen ether-based solvent in an amount of 0.1 wt% or less with improved mechanical properties as well as excellent transparency and flexibility, a method of preparing the same, and a molded article prepared by using the polyalkylene carbonate-polylactic acid composite.
C08J 3/09 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids
C08L 67/02 - Polyesters derived from dicarboxylic acids and dihydroxy compounds
C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
C08L 69/00 - Compositions of polycarbonatesCompositions of derivatives of polycarbonates
64.
FILLER COMPRISING HYALURONIC ACID HYDROGEL HAVING EXCELLENT FILLING PROPERTIES
A hyaluronic acid hydrogel incorporating cross-linked hyaluronic acid is provided for cosmetic uses in alleviating the appearance of wrinkles and other
skin conditions which are improved by adding volume to the affected tissues. The invented filler is characterized by a custom parameter value (WIE) related to its filling abilities, developed using microrheology technology. The invented filler thus exhibits improved high viscoelasticity flow properties, has low mobility when injected into skin while still maintaining the shape thereof, and thus has excellent soft tissue restoration properties, for example for the cheeks, breasts, nose, lips or bottom, and excellent volume expansion and wrinkle alleviation properties.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
The present invention relates to polyethylene having a high degree of cross-linking, and a cross-linked polyethylene pipe comprising the same. The polyethylene according to the present invention has an ultra-high molecular weight so as to have increased cross-linking speed, thereby exhibiting a sufficient degree of cross-linking even when cross-linking time is short, and thus can exhibit excellent strength and pressure resistance.
C08F 2/38 - Polymerisation using regulators, e.g. chain terminating agents
C08F 4/646 - Catalysts comprising at least two different metals, in metallic form or as compounds thereof, in addition to the component covered by group
C08F 4/659 - Component covered by group containing a transition metal-carbon bond
C08F 4/6592 - Component covered by group containing a transition metal-carbon bond containing at least one cyclopentadienyl ring, condensed or not, e.g. an indenyl or a fluorenyl ring
The present disclosure relates to a crosslinked polyethylene pipe having excellent physical properties. The crosslinked polyethylene pipe according to the present disclosure has optimized the degree of crosslinking and storage modulus by finding out the optimum physical property range between the degree of crosslinking and the storage modulus which have a mutual trade-off relationship, whereby the crosslinked polyethylene pipe according to the present disclosure has excellent long-term durability and short-term pressure resistance, and thus can be applied to various fields requiring these physical properties.
Disclosed are: a fusion polypeptide comprising growth differentiation factor 15 (GDF15) and a polypeptide region capable of O-glycosylation; a pharmaceutical composition comprising the fusion polypeptide; and a method for increasing the in vivo duration of GDF15, comprising the step of fusing a polypeptide region capable of O-glycosylation.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to an amide derivative compound, which exhibits the activity of a diacylglycerol acyltransferase (DGAT) 2 inhibitor and is represented by chemical Formula (1) or a pharmaceutically acceptable salt or isomer thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof.
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
69.
COMPOSITION COMPRISING ANTIGEN-PRESENTING CELL CO-EXPRESSING MHC AND TUMOR ANTIGEN, AND CANCER TREATMENT USING SAME
The present invention relates to a vaccine composition for preventing or treating cancer comprising antigen-presenting cells, on the cell surface of which a composite of major histocompatibility complex (MHC) and tumor antigen is overexpressed.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/74 - Major histocompatibility complex [MHC]
The present invention relates to a novel compound of the general Formula I, wherein the compound is useful as an agent for treatment or prophylaxis of various metabolic diseases such as obesity or diabetes and hyperlipidemia, by means of excellent GLP-1 agonist activity and an excellent DMPK profile, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method for preparing the compound.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Provided is a method of preparing isopropyl alcohol including: supplying a feed stream including a propylene monomer and water to a reaction unit and performing a reaction to produce a reaction product including isopropyl alcohol, the propylene monomer, and the water; supplying a first discharge stream including a gaseous reaction product and a second discharge stream including a liquid reaction product which are discharged from the reaction unit to a stripper, respectively; and in the stripper, circulating an upper discharge stream including the propylene monomer to the reaction unit and supplying a lower discharge stream including water and isopropyl alcohol to an isopropyl alcohol purification unit, wherein the first discharge stream is condensed by a first heat exchanger and supplied as a liquid phase to the striSpper.
C07C 29/04 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by addition of hydroxy groups to unsaturated carbon-to-carbon bonds, e.g. with the aid of H2O2 by hydration of carbon-to-carbon double bonds
C07C 29/76 - SeparationPurificationStabilisationUse of additives by physical treatment
72.
MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide and that comprise an epitope-presenting Wilms tumor peptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.
The present application relates to a use for cartilage regeneration and/or use for osteoarthritis treatment of a mesenchymal stem cell expressing TSG-6 protein. The present application provides a composition for cartilage regeneration and a pharmaceutical composition for osteoarthritis treatment, comprising a mesenchymal stem cell expressing TSG-6 protein as an active ingredient. The composition for cartilage regeneration and/or the pharmaceutical composition for osteoarthritis treatment provided by the present application can increase collagen expression of cartilage cells, reduce inflammation, and restore the cartilage structure.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
74.
USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
75.
METHOD FOR PREPARING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
The present invention relates to a pharmaceutical composition comprising crystalline particles comprising the compound of Formula 1 or a pharmaceutically acceptable salt thereof comprising the compound of Formula 2 below in an amount of 0.2 wt.% or less. The crystalline particles according to the present invention, have a size, shape and distribution that improve uniformity and flowability as well as being optimized for input into the preparation process of the finished drug product, thereby increasing the content uniformity in the preparation process of the finished product and minimizing breakage during compressing into tablets, and thus can be used as a raw material pharmaceutical product suitable for the preparation process of the finished drug product. ?Representive figure? FIG. 1
The present invention relates to a crystalline form I represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form I represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
77.
CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
The present invention relates to a crystalline form III represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form III represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
78.
ORAL FORMULATION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID AND METHOD FOR PREPARING SAME
The present invention relates to an oral formulation comprising an API selected from 1-(3-cyano-1-isopropylindol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof in high content. Since the oral formulation according to the present invention has a high content and excellent physical properties by comprising a glidant in excipients, economic efficiency and the convenience of administration can be increased.
The present invention relates to use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as a selective agonist of the melanocortin-4-receptor (MC4R).
The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.
The present invention relates to a method of preparing a positive electrode active material having a high ratio of charge and discharge capacity at a charge end voltage of 4.1 V to 4.175 V to charge and discharge capacity at a charge end voltage of 4.2 V to 4.275 V and an excellent initial charge and discharge capacity.
C01G 53/44 - Complex oxides containing nickel and at least one other metal element containing alkali metals, e.g. LiNiO2 containing manganese
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
The present invention relates to a composite formulation for oral administration comprising an active pharmaceutical ingredient (API) selected from 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein the API has a particle size of granules corresponding to 90% of the maximum particle size in the cumulative particle size distribution (D(0.9)) of 80 ?m or more and 300 ?m or less. The composite formulation for oral administration according to the present invention has a low friability and an increased dissolution rate even if a high content of API is included, by regulating the particle size of the API to a certain range.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
The present invention relates to a crystal form IV of organic acid salts of a compound represented by chemical formula 1, a preparation method thereof, and a pharmaceutical composition comprising same. The crystal form IV of organic acid salts of the compound represented by chemical formula 1 of the present invention may be characterized by an XRPD pattern, a DSC profile and/or a TGA profile.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
85.
POLYLACTIDE RESIN COMPOSITION EXCELLENT IN CYSTALLIZATION HALF-LIFE, AND METHOD FOR PREPARING THE SAME
The present disclosure relates to a polylactide resin composition that is used in combination with a specific nucleating agent, which is excellent in crystallization half-life and crystallinity degree, and thus, can maintain the properties inherent in the polylactide resin according to the present disclosure while having excellent processability.
The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or preventing a hyperuricemia-related disease using the same, and the pharmaceutical composition of the present invention may effectively reduce the blood uric acid concentration in a patient with a hyperuricemia-related disease.
The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or preventing a hyperuricemia-related disease using the same, and the pharmaceutical composition of the present invention may effectively reduce the blood uric acid concentration in a patient with a hyperuricemia-related disease.
The present invention relates to a method for synthesizing carbon nanotubes by using a nanoparticle catalyst prepared by condensation after vaporization of catalytic raw material using plasma. When the manufacturing method of the present invention is used, the synthesized carbon nanotubes may have high crystallinity, and mass synthesis may be facilitated.
The present invention relates to a carbon nanotube manufacturing apparatus including a plasma device and a CVD reactor which are connected in series, in which a nanoparticle catalyst in an aerosol state prepared in the plasma device is transferred into the CVD reactor to synthesize carbon nanotubes, and thus carbon nanotubes having excellent physical properties can be continuously synthesized.
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
B01J 19/08 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor
B01J 19/24 - Stationary reactors without moving elements inside
C01B 32/162 - Preparation characterised by catalysts
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
Provided is a method of preparing IPA including a purification step using a plurality of column, in which in a first column, an upper stream including a mixture of IPA, NPA, and water and a lower stream including water and high-boiling point organic substances are separated from a feed stream including IPA, NPA, water, and high-boiling point organic substances, in a second column, a lower stream including IPA and NPA and an upper stream in which a solvent forms a three-component azeotropic mixture with water and IPA are discharged from the upper stream of the first column, using the organic solvent, and in a third dividing wall column, a stream in which a branch stream of the lower stream of the first column and the lower stream of the second column are mixed is supplied to a first area, an upper stream including water from which high-boiling point organic substances have been removed, a side stream including IPA from which NPA has been removed, and a lower stream including the high-boiling point organic substances and NPA are separated from the mixed stream, and the side stream including IPA is recovered from the second area.
The present invention relates to a single-particle positive electrode active material capable of providing a battery having improved initial resistance and lifespan, a method for preparing the same, and a positive electrode including the same, and relates to a single-particle positive electrode active material having a (cos?)2 value of 0.5 or greater wherein ? represents an angle between a long axis of a crystal grain obtained through electron backscatter diffraction (EBSD) analysis and a lithium migration path, a method for preparing the same, and a positive electrode including the same.
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
93.
POSITIVE ELECTRODE ACTIVE MATERIAL AND POSITIVE ELECTRODE INCLUDING SAME
The present invention relates to a positive electrode active material capable of achieving a battery with improved initial resistance characteristics and life characteristics and a positive electrode including the same, and to a positive electrode active material in a form of a single particle, wherein, after a positive electrode, which includes a positive electrode active material layer containing 80 wt% or more of the positive electrode active material based on a total weight of the positive electrode active material layer, is rolled such that density of the positive electrode active material layer after the rolling is 2.7 g/cm3 or more, when the positive electrode active material layer is analyzed by X-ray diffraction (XRD), a ratio of an area of a (003) peak to an area of all peaks identified in a 2A range of 10 to 90 satisfies 30% or more, and a positive electrode including the same.
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
94.
METHANE-REFORMING CATALYST AND PREPARATION METHOD THEREFOR
A methane-reforming catalyst according to one embodiment of the present application comprises: a porous metal support; a first coating layer, which is provided on the porous metal support and comprises an inorganic oxide; and a second coating layer, which is provided on the first coating layer and comprises a perovskite-based compound represented by chemical formula 1, wherein the inorganic oxide comprises CeO2 or Al2O3.
C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
The present invention relates to an injectable formulation containing, as an active pharmaceutical ingredient (API), an isoxazoline derivative or pharmaceutically acceptable salt thereof useful as a caspase inhibitor. The injectable formulation according to the present invention includes a first agent composed of a high dose of the API, and a second agent that is a solvent capable of dissolving the first agent, and may be prepared by mixing the first agent and the second agent immediately before administration. The injectable formulation stably contains the active API and thus has the advantage that effective drug efficacy can be expected when administered to a patient.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
96.
POSITIVE ELECTRODE ACTIVE MATERIAL PRECURSOR, METHOD FOR PREPARING THE SAME, POSITIVE ELECTRODE ACTIVE MATERIAL, AND METHOD FOR PREPARING POSITIVE ELECTRODE ACTIVE MATERIAL
The present invention relates to a positive electrode active material precursor, a method for preparing the same, a positive electrode active material, and a method for preparing a positive electrode active material, and provides: a positive electrode active material precursor including Ni and Mn and secondary particles formed by the aggregation of a plurality of primary particles, wherein the secondary particles have a ratio of a core area to a total area of the particles (core area/total area) of 28.7% to 34.1%, and the porosity represented by Equation 1 below is 11.3% to 11.7%; a method for preparing the positive electrode active material precursor; a positive electrode active material including a reaction product of the positive electrode active material precursor and a lithium raw material; and a method for preparing a positive electrode active material using the positive electrode active material precursor.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
97.
POLYBUTYLENE ADIPATE TEREPHTHALATE RESIN COMPOSITION, AND A METHOD FOR PREPARING THE SAME
The present invention relates to a polybutyleneadipate terephthalate resin composition, and a method for preparing the same. The polybutyleneadipate terephthalate resin composition includes a polybutyleneadipate terephthalate resin, a chain extender, and a gel reducer, and suppresses gel formation, thus being excellent in terms of mechanical properties and external appearance.
The preset invention relates to a use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for preventing or treating rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway, particularly rare genetic obesity diseases associated with proopiomelanocortin (POMC) deficiency.
POSITIVE ELECTRODE ACTIVE MATERIAL PRECURSOR, METHOD FOR PREPARING POSITIVE ELECTRODE ACTIVE MATERIAL USING SAME, AND POSITIVE ELECTRODE ACTIVE MATERIAL
The present invention is an invention which relates to a positive electrode active material precursor capable of implementing a positive electrode active material in the form of a single particle even when heat-treated at a low temperature, and specifically, to a positive electrode active material precursor which includes a first positive electrode active material precursor having a composition represented by Formula 1 described herein and including a composite transition metal in the form of a single particle, and one or more of a second positive electrode active material precursor having a composition represented by Formula 2 described herein and a third positive electrode active material precursor having a composition represented by Formula 3 described herein, a method for preparing a positive electrode active material using the positive electrode active material precursor, and a positive electrode active material prepared by the method.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
100.
POSITIVE ELECTRODE ACTIVE MATERIAL AND METHOD OF PREPARING THE SAME
The present invention relates to a positive electrode active material in a form of a single particle, which includes a lithium transition metal oxide in a form of a single particle; a coating portion containing cobalt which is formed on the lithium transition metal oxide in the form of a single particle; and LiCoO2 in a form of an island which is discontinuously formed on a surface, wherein a ratio of an intensity of a peak (550 cm-1 to 620 cm-1) corresponding to an A1g vibration mode of LiCoO2 to an intensity of a peak (500 cm-1 to 600 cm-1) corresponding to an A1g vibration mode of LiNiO2 in a Raman spectrum of the surface is greater than 1, and a method of preparing the same.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
patents
